Unibest
← Back to patent-cliff list

CAS 371-40-4

4-fluoroaniline1-Amino-4-fluorobenzene

Codes: CABO-009, Imipenem-016

Application context (from source-drug indications)

Neuroendocrine tumourCabozantinib S-malatePancreatic neuroendocrine tumourCabozantinib S-malateRenal cell carcinomaCabozantinib S-malateHepatocellular carcinomaCabozantinib S-malateThyroid cancerCabozantinib S-malateNeuroendocrine carcinomaCabozantinib S-malateBacterial pneumoniaCilastatin Sodium/Imipenem/RelebactamHospital-acquired pneumoniaCilastatin Sodium/Imipenem/RelebactamInfectious diseaseCilastatin Sodium/Imipenem/RelebactamBacteraemiaCilastatin Sodium/Imipenem/RelebactamVentilator-associated pneumoniaCilastatin Sodium/Imipenem/RelebactamHealthcare-associated pneumoniaCilastatin Sodium/Imipenem/RelebactamBacterial infectionImipenemGonorrhoeaImipenemBacillus anthracis infectionImipenem

Source drugs (routes using this intermediate)

DrugTierExpiry
Cabozantinib S-malateTier B — Position early2029
Cilastatin Sodium/Imipenem/RelebactamTier C — Watch / trade-
ImipenemTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Cilastatin Sodium/Imipenem/RelebactamOptimised routesteps: 9total yield: /
4-Methoxyphenylamine→1-Amino-4-fluorobenzene→4-Bromophenylamine→4-Ethoxyphenylamine→omega-Bromoacetophenone→Chloroacetyl chloride→2-Iodo-1-(3-methoxyphenyl)ethanone→1-Bromo-3,3-dimethylbutan-2-one<-fgf->→2-[(4-Methoxyphenyl)amino]-1-phenylethanone→1-[(4-Methoxyphenyl)amino]acetone→1-[(4-Fluorophenyl)amino]acetone→2-[(4-Bromophenyl)amino]-1-(3-methoxyphenyl)ethanone→1-[(4-Ethoxyphenyl)amino]-3,3-dimethylbutan-2-one→(3S)-4-Benzoyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-(2,2-dimethylpropanoyl)-1-(4-ethoxyphenyl)azetidin-2-one→(2R,3R)-3-Methyloxirane-2-carboxylic acid→L-Threonine→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxo-2-phenylethyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Fluorophenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Bromophenyl)-N-[2-(3-methoxyphenyl)-2-oxoethyl]-3-methyloxirane-2-carboxamide→(2R,3R)-N-(3,3-Dimethyl-2-oxobutyl)-N-(4-ethoxyphenyl)-3-methyloxirane-2-carboxamide→(3S)-4-Benzoyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-1-(4-fluorophenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-hydroxyethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-4-(2,2-Dimethylpropanoyl)-1-(4-ethoxyphenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(1E)-1-[(4-Methoxyphenyl)imino]acetone→S-Pyridin-2-yl (3R)-3-[[tert-butyl(dimethyl)silyl]oxy]butanethioate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-ethoxyphenyl)-4-oxoazetidin-2-yl acetate→(2S,3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate
ImipenemOptimised routesteps: 9total yield: /
4-Methoxyphenylamine→1-Amino-4-fluorobenzene→4-Bromophenylamine→4-Ethoxyphenylamine→omega-Bromoacetophenone→Chloroacetyl chloride→2-Iodo-1-(3-methoxyphenyl)ethanone→1-Bromo-3,3-dimethylbutan-2-one<-fgf->→2-[(4-Methoxyphenyl)amino]-1-phenylethanone→1-[(4-Methoxyphenyl)amino]acetone→1-[(4-Fluorophenyl)amino]acetone→2-[(4-Bromophenyl)amino]-1-(3-methoxyphenyl)ethanone→1-[(4-Ethoxyphenyl)amino]-3,3-dimethylbutan-2-one→(3S)-4-Benzoyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-(2,2-dimethylpropanoyl)-1-(4-ethoxyphenyl)azetidin-2-one→(2R,3R)-3-Methyloxirane-2-carboxylic acid→L-Threonine→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxo-2-phenylethyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Methoxyphenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Fluorophenyl)-3-methyl-N-(2-oxopropyl)oxirane-2-carboxamide→(2R,3R)-N-(4-Bromophenyl)-N-[2-(3-methoxyphenyl)-2-oxoethyl]-3-methyloxirane-2-carboxamide→(2R,3R)-N-(3,3-Dimethyl-2-oxobutyl)-N-(4-ethoxyphenyl)-3-methyloxirane-2-carboxamide→(3S)-4-Benzoyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-3-[(1R)-1-hydroxyethyl]-1-(4-methoxyphenyl)azetidin-2-one→(3S)-4-Acetyl-1-(4-fluorophenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(3S)-1-(4-Bromophenyl)-3-[(1R)-1-hydroxyethyl]-4-(3-methoxybenzoyl)azetidin-2-one→(3S)-4-(2,2-Dimethylpropanoyl)-1-(4-ethoxyphenyl)-3-[(1R)-1-hydroxyethyl]azetidin-2-one→(1E)-1-[(4-Methoxyphenyl)imino]acetone→S-Pyridin-2-yl (3R)-3-[[tert-butyl(dimethyl)silyl]oxy]butanethioate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-fluorophenyl)-4-oxoazetidin-2-yl acetate→(2R,3R)-1-(4-Bromophenyl)-3-[(1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-ethoxyphenyl)-4-oxoazetidin-2-yl acetate→(2S,3S)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid→(2R,3R)-3-[(1R)-1-[[tert-Butyl(dimethyl)silyl]oxy]ethyl]-4-oxoazetidin-2-yl acetate

Intermediates available on this site

Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.

SupplierProductPrice bandMOQLead timeQualificationsAction
Unibest Nantong cGMP Site4-Hydroxy-6,7-dimethoxyqunioline
Pharmaceutical Intermediates
On requestOn requestOn request
—
Unibest Taizhou GMP-like Site4-((6,7-Dimethoxyquinolin -4-yl)oxy)aniline
Pharmaceutical Intermediates
On requestOn requestOn request
—
Qualified Partner — East China API Works1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid
Pharmaceutical Intermediates
On requestOn requestOn request
—

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.